EXACT Therapeutics AS announces start date of 06/06/2022 for its new CEO Per Walday, relocation of some activities to Oslo and Dominic Moreland stepping down as CFO
OSLO/LONDON, 13 May 2022: EXACT Therapeutics AS (“EXACT-Tx” or “the Company“) Euronext Growth: EXTX), a clinical stage biopharmaceutical company with a mission to enhance the therapeutic efficacy of medicines through ultrasound-mediated drug delivery, today announces that its new Chief Executive Officer (“CEO“) Per Walday will start 6 June 2022.
As announced by the Company on 28th March 2022, Per, who worked alongside the Founders and some of the Board Members of EXACT-Tx during his time as Global Head of Project Management at GE Healthcare, is joining EXACT-Tx as CEO. During his time at GE Healthcare, he was responsible for all development programs of new pharmaceutical products which included R&D efforts within the field of ultrasound and microbubbles which paved the way for what would become years later EXACT-Tx’ Acoustic Cluster Therapy (ACT®). Per was most recently CEO of PCI Biotech (OSE: PCIB) with a technology involving a drug-device combination developed for use in the field oncology. The experience and wealth of knowledge that he has acquired in those fields will be of enormous help to the success of ACT®.
Dr Masha Strømme, Executive Board Chair, commented: “The Board and I look forward to working with Per. His intimate knowledge of ultrasound along with therapeutic expertise and strong leadership will lead the Company through the next phase of its development.”
Dr Per Walday, Chief Executive Officer-designate of EXACT-Tx, said: “Remarkable innovation and progress have been made with the ACT® platform since I led the development of related ultrasound technology initially aimed for diagnostic use in GE Healthcare. I am very excited to be joining EXACT- Tx in June and aim to further maximise the value of the innovative ACT® platform for ultrasound mediated drug enhancement and accelerate our journey towards becoming a leading precision health company.”
As a result of Per’s appointment, some of the activities of EXACT-Tx will be relocated to Oslo. Dominic Moreland will be stepping down as Chief Financial Officer (“CFO“). Dominic has a three month notice period and he will work in the transition period with Ole Fegth who will then assume the role of interim CFO. The Board of EXACT-Tx thanks Dominic for his contribution.
END
For more information, please contact:
Masha Strømme, Executive Chair of the Board of Exact Therapeutics AS
Exact-Therapeutics email: Masha@EXACT-tx.com
Dominic Moreland, CFO
EXACT Therapeutics Email: Dominic@EXACT-tx.com
About Exact-Therapeutics AS
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.
Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause Actual results and developments to differ materially from those expressed or implied by this forward-looking statement.